NCT01973088UnknownNot Applicable
Screening and Identification of Human Urate Transporter hURAT1 MicroRNA
Qian-wei Li0 sites80 target enrollmentStarted: November 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 80
- Primary Endpoint
- micro-RNA
Study Overview
Brief Summary
This study intends to use in patients with renal tissue and blood samples, screening and identification of renal tissue hURAT1 regulating the expression of micro-RNA, for further study of uric acid stone formation mechanism and the occurrence of clinical preventive uric acid stones provide new clues and new intervention targets.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •A、B group were enrolled standards: ① aged 18-65 years old; ② comply with percutaneous nephrolithotomy lithotripsy indications for surgery; ③ ECT tips ipsilateral normal or mildly impaired renal function.
- •Group C patients were enrolled standards: ① aged 18-65 years old; ② normal renal function, not associated with urinary calculi in patients; ③ cancer patients met radical nephrectomy indications for surgery; ④ emergency trauma patients suffering from kidney resection surgical indications.
Exclusion Criteria
- •aged <18 years or> 65 years; ② neurological disease or cognitive dysfunction; ③ can not be corrected or uncorrected coagulopathy; ④ associated with diabetes, hypertension and other metabolic diseases; ⑤ accompanied by tuberculosis, hepatitis, HIV and other infectious diseases; ⑥ poor tolerance to anesthesia and surgery, such as: severe cardiopulmonary disease, coagulation disorders, etc.; ⑦ ultrasound, renal imaging examination revealed renal cortex was significantly thinner (renal cortical thickness <1.5cm), structural variation; ⑧ with severe systemic or urinary tract infection; ⑨ ECT tips ipsilateral renal function is severely impaired or solitary kidney.
Outcomes
Primary Outcomes
micro-RNA
Time Frame: 6 months
microRNA microarray:the micro-RNA of kidney tissue
Secondary Outcomes
- 24h urine quantitative analysis(96 hours)
- Urine(24 hours)
- Blood biochemistry(24 hours)
- Stone analysis(3 weeks)
- hURAT1 transporter protein(6 months)
Investigators
Qian-wei Li
Southwest Hospital, China
Southwest Hospital, China
Similar Trials
Completed
Not Applicable
Urine Albendazole Levels for Coverage AssessmentHelminthiasisNCT04041427Universidad Nacional de Salta12
Completed
Not Applicable
Evaluation of Urine Samples and Their Relation to Urinary Tract InfectionUrinary Tract InfectionsNCT03522766Coloplast A/S30
Completed
Not Applicable
Urine Testing to Detect Kidney Transplant RejectionKidney TransplantationKidney DiseaseKidney Failure, ChronicNCT00337220National Institute of Allergy and Infectious Diseases (NIAID)492
Terminated
Not Applicable
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate CancerProstate CancerNCT03256630Genomic Health®, Inc.128
Terminated
Not Applicable
Search for New Methods to Detect Acute Renal FailureKidney FailureHealthy VolunteersRenal Tubular ToxicityKidney DiseaseKidney Failure, ChronicNCT00026702National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)226